I strongly agree with you here, the best outcome for all stakeholders is to sell to a big Pharma where they have the firepower to push development and cover a lot more patients expeditiously than cherry-picking which indications to develop in-house. No doubt a company can succeed long term with just one or two drugs treating a handful of indications, but it doesn't appear to me Neuren has long term ambitions to become an entrenched Pharma company in which they take risk buying acquisitions to further their own pipeline. This is a very small team that is fundamentally unprepared for long term empire building (I mean that with all due respect, they do a fantastic job with what they have already). But imo a takeover is a clean break: it keeps the drugs IP and research together, and the aquirer is highly motivated to commercialise the drugs having paid a pretty penny for them whereby the reach to treat the most patients possible is greatest.
NEU Price at posting:
$19.71 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)